Back to Search
MATTHEW MCCLUNG, PHARMD
PHARMD
Pharmacist
NPI: 1518469949Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
12409(NE)
Research & Publications (20)
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
PMID 17468062·Bone·2007
4-observational
Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies.
PMID 16527005·Curr Osteoporos Rep·2006
6-review
Use of highly potent bisphosphonates in the treatment of osteoporosis.
PMID 16036074·Curr Osteoporos Rep·2003
6-review
The menopause and HRT. Prevention and management of osteoporosis.
PMID 12763512·Best Pract Res Clin Endocrinol Metab·2003
6-review
Clinical risk factors and evaluation of the risk of osteoporosis in clinical practice.
PMID 11033474·Ann Med Interne (Paris)·2000
6-review
Bisphosphonates in osteoporosis: recent clinical experience.
PMID 11249544·Expert Opin Pharmacother·2000
6-review
The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?
PMID 19287893·Salud Publica Mex·2009
6-review
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
PMID 19671655·N Engl J Med·2009
4-observational
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
PMID 18950736·Bone·2009
2-rct
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
PMID 18087660·Osteoporos Int·2008
3-trial
Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.
PMID 18226668·Contraception·2008
1-meta
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
PMID 18539106·Bone·2008
3-trial
Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
PMID 17968610·Osteoporos Int·2008
8-other
European guidance for osteoporosis: an American perspective.
PMID 18846979·Pol Arch Med Wewn·2008
8-other
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
PMID 17920005·Bone·2008
2-rct
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis.
PMID 17938984·Osteoporos Int·2008
4-observational
Fracture risk remains reduced one year after discontinuation of risedronate.
PMID 17938986·Osteoporos Int·2008
2-rct
Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
PMID 17726081·J Clin Endocrinol Metab·2007
4-observational
"Because I know it will!": placebo effects of an ergogenic aid on athletic performance.
PMID 17876973·J Sport Exerc Psychol·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 100 BLUFF AVE
WINNEBAGO, NE 68071 - Phone
- (402) 878-3692
Quick Facts
- NPI
- 1518469949
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile